Australian judge dismisses lawsuit claiming Bayer weedkiller causes blood cancer
Recasts and writes through with comments from judge, Bayer and plaintiffs' lawyers
By Peter Hobson and Alasdair Pal
CANBERRA, July 25 (Reuters) -An Australian judge on Thursday dismissed a class action lawsuit claiming Bayer's BAYGn.DE Roundup weedkiller can cause a type of blood cancer, a ruling the company said it would seek to leverage in similar cases being fought in the United States.
More than 1,000 people had joined the lawsuit, claiming Roundup's active ingredient, glyphosate, caused their non-Hodgkins lymphoma (NHL).
Justice Michael Lee of Australia's Federal Court said in his ruling he had reviewed three types of scientific studies - epidemiological, animal studies and mechanistic evidence - that looked at the links between glyphosate and lymphoma and was not satisfied there was sufficient evidence that the chemical caused the cancer in humans.
"It is not proven in this proceeding on a balance of probabilities... that throughout the relevant period use of, and or exposure to Roundup products increased an individual's risk of developing NHL," Lee said.
The claimants' law firm, Maurice Blackburn, said it was reviewing the ruling before deciding whether to appeal.
The lead claimant, 41-year-old Kelvin McNickle, said he used Roundup to spray weeds for over two decades on his family's property and while working for a vegetation management company. He developed non-Hodgkins lymphoma aged 35.
Bayer, a German chemicals and pharmaceuticals company, has long maintained that Roundup and glyphosate are safe. It has been battling lawsuits over Roundup in the United States since it bought the product's owner Monsanto in 2018. It still faces more than 50,000 outstanding Roundup claims there.
It has prevailed in 14 of the last 20 U.S. trials but racked up a string of losses in late 2023 and early 2024, with more than $4 billion in damages awarded. Some of the amounts awarded have since been reduced but the string of wins for plaintiffs shattered investor and company hopes that the worst of the Roundup litigation was over.
Unlike the U.S., class actions in Australia are not decided by a jury.
Bayer spokesman Philipp Blank said that while said the Australian and U.S. judicial systems were very different, "we will of course try to leverage the conclusion of the very science-based approach from the Australian legal system in the litigation in the U.S."
The class action brought by Maurice Blackburn against Bayer subsidiaries is one of around 40 similar cases that have been filed outside the United States, most of them in Canada.
Some farmers in Australia had worried that if the court had ruled glyphosate could cause lymphoma, it could lead to stricter regulation and restrict its use.
The National Farmers’ Federation said in a statement that the country's farmers had put their faith in the Australian Pesticides and Veterinary Medicine Authority to ensure the safety of products they use and that Thursday's ruling had reinforced that the regulator was doing its job.
"This is a win for Australian farmers," said Warren Inwood, a Bayer executive in Australia.
Roundup has been in use around the world since the 1970s.
The product has been under scrutiny since the World Health Organization's cancer research agency concluded in 2015 that glyphosate was probably carcinogenic to humans, though without concluding whether it posed a risk in real-world use.
Bayer has replaced glyphosate with new active ingredients in its products for household use in the United States to reduce the risk of litigation as most claims have come from home users.
It continues to sell glyphosate-based weedkillers to farmers, who rely on it heavily.
Reporting by Peter Hobson in Canberra and Alasdair Pal in Sydney; Editing by Edwina Gibbs
면책조항: XM Group 회사는 체결 전용 서비스와 온라인 거래 플랫폼에 대한 접근을 제공하여, 개인이 웹사이트에서 또는 웹사이트를 통해 이용 가능한 콘텐츠를 보거나 사용할 수 있도록 허용합니다. 이에 대해 변경하거나 확장할 의도는 없습니다. 이러한 접근 및 사용에는 다음 사항이 항상 적용됩니다: (i) 이용 약관, (ii) 위험 경고, (iii) 완전 면책조항. 따라서, 이러한 콘텐츠는 일반적인 정보에 불과합니다. 특히, 온라인 거래 플랫폼의 콘텐츠는 금융 시장에서의 거래에 대한 권유나 제안이 아닙니다. 금융 시장에서의 거래는 자본에 상당한 위험을 수반합니다.
온라인 거래 플랫폼에 공개된 모든 자료는 교육/정보 목적으로만 제공되며, 금융, 투자세 또는 거래 조언 및 권고, 거래 가격 기록, 금융 상품 또는 원치 않는 금융 프로모션의 거래 제안 또는 권유를 포함하지 않으며, 포함해서도 안됩니다.
이 웹사이트에 포함된 모든 의견, 뉴스, 리서치, 분석, 가격, 기타 정보 또는 제3자 사이트에 대한 링크와 같이 XM이 준비하는 콘텐츠 뿐만 아니라, 제3자 콘텐츠는 일반 시장 논평으로서 "현재" 기준으로 제공되며, 투자 조언으로 여겨지지 않습니다. 모든 콘텐츠가 투자 리서치로 해석되는 경우, 투자 리서치의 독립성을 촉진하기 위해 고안된 법적 요건에 따라 콘텐츠가 의도되지 않았으며, 준비되지 않았다는 점을 인지하고 동의해야 합니다. 따라서, 관련 법률 및 규정에 따른 마케팅 커뮤니케이션이라고 간주됩니다. 여기에서 접근할 수 있는 앞서 언급한 정보에 대한 비독립 투자 리서치 및 위험 경고 알림을 읽고, 이해하시기 바랍니다.
